Product Description
Topical clotrimazole is used to treat tinea corporis (ringworm; fungal skin infection that causes a red scaly rash on different parts of the body), tinea cruris (jock itch; fungal infection of the skin in the groin or buttocks), and tinea pedis (athlete's foot; fungal infection of the skin on the feet and between the toes). Clotrimazole is in a class of antifungal medications called imidazoles. It works by stopping the growth of fungi that cause infection. (Sourced from: https://medlineplus.gov/druginfo/meds/a618059.html)
Mechanisms of Action: Sterol Synthesis Inhibitor,CYP51A1 Inhibitor,Fungal Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal,Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location: LEVERKUSEN 2M D-51368
Company CEO: Werner Baumann
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belarus, Germany, Russia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Candidiasis|Candidiasis, Vulvovaginal|Otitis Externa|Otomycosis|Vulvovaginitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 21-01/ClotriBet-S | P3 |
Recruiting |
Candidiasis |
2025-12-01 |
|
| Clotrimazole+Lactulose-II/III | P3 |
Recruiting |
Vulvovaginitis|Candidiasis, Vulvovaginal |
2025-09-30 |
9% |
| CLEAR 2 | P3 |
Active, not recruiting |
Otitis Externa|Otomycosis |
2021-03-13 |